Rimegepant (Nurtec ODT) vs Zavegepant (Zavzpret)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: CGRP receptor · full Migraine pipeline

Rimegepant (Nurtec ODT)

Marketed by Pfizer and partners

Approved in Migrainesmall molecule
Reliable signal

NCT03235479 · Phase 3 · completed

This was a randomized, triple-masked, placebo-controlled trial with 1,162 randomized participants. Its two primary clinical endpoints were met: 2-hour pain freedom was 19.2% with rimegepant versus 14.2% with placebo (p=0.0298), and freedom from the most bothersome symptom was 36.6% versus 27.7% (p=0.0016).

Next expected readout: November 2026 · NCT06641466 (registry estimate)

Reported efficacy

Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14) (met)

Result source: NCT05810038

Zavegepant (Zavzpret)

Marketed by Pfizer

Approved in Migrainesmall molecule
Reliable signal

NCT04571060 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial, with 623 zavegepant-treated and 646 placebo-treated participants included in the efficacy analysis. Both prespecified primary clinical endpoints were met: pain freedom and freedom from the most bothersome symptom at 2 hours were significantly higher with zavegepant than placebo.

Next expected readout: March 2027 · NCT06401642 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Zavegepant (Zavzpret): registry results are on file for Migraine, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Rimegepant (Nurtec ODT)
Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase (OP and Weeks 9 to 12 of the DBT phase): Rimegepant - Randomization Phase -4.3 Total Migraine Days per Month (95% CI -4.83 to -3.87) | Placebo - Randomization Phase -3.5 Total Migraine Days per Month (95% CI -4 to -3.04) NCT03732638 · Phase 2/3 · design grade: moderate · reviewed ClinicalTrials.gov result
Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14) NCT05810038 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase (Baseline, Week 9 to Week 12 of the DBT phase): Rimegepant -2.4 Days/month (95% CI -2.93 to -1.96) | Placebo -1.4 Days/month (95% CI -1.87 to -0.91) NCT05399485 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rimegepant (Nurtec ODT)'s landscape · Zavegepant (Zavzpret)'s landscape